Trinity Biotech Repositions for AI-Driven Growth with CGM+ Biosensor Platform
Trinity Biotech has unveiled CGM+, a next-generation, AI-native continuous glucose monitoring (CGM) biosensor platform designed to advance digital health and personalized medicine.123
CGM+ combines glucose monitoring with additional sensors for heart activity, body temperature, sleep, and physical activity, providing an integrated view of metabolic and physiological health.123
The platform is engineered as both a clinical and consumer device, supporting regulated workflows and everyday health optimization through real-time, AI-driven analytics.2
CGM+ is positioned as a proprietary data engine for the AI health ecosystem, enabling predictive, preventative care and new commercial business models including device sales and AI-based data services.123
A strategic realignment within Trinity Biotech reflects the focus on AI-driven CGM technology, with preparations underway for FDA submission in 2026 and plans for commercial launch around mid-2026.13
The company has undergone operational restructuring—streamlining manufacturing and corporate services—to increase efficiency and expects to be cash-flow positive by September 2025.3
Trinity Biotech is also collaborating with PulseAI to enhance its multi-parameter biosensor data analytics, aiming to further differentiate its AI-powered CGM solution for diabetes and holistic health.4
Sources:
1. https://www.drugdeliverybusiness.com/trinity-biotech-unveils-next-gen-ai-powered-cgm-biosensor/
2. https://hitconsultant.net/2025/07/24/trinity-biotech-unveils-cgm-ai-native-wearable-biosensor-for-holistic-health-monitoring/
3. https://www.fiercebiotech.com/medtech/trinity-biotech-outlines-plans-wearable-cgm-biosensor-platform
4. https://www.globenewswire.com/fr/news-release/2024/05/16/2883525/8624/en/Trinity-Biotech-Announces-Strategic-Collaboration-with-Medical-Artificial-Intelligence-Company-PulseAI.html